PMC:3406298 / 1153-1594 JSONTXT

{"target":"http://pubannotation.org/docs/sourcedb/PMC/sourceid/3406298","sourcedb":"PMC","sourceid":"3406298","source_url":"https://www.ncbi.nlm.nih.gov/pmc/3406298","text":"Results\nOne hundred and four subjects were randomised with 52 in each group. Ninety-five subjects (47 and 48 subjects in RCM-102 and placebo groups) completed the trial. Nine subjects withdrew from the study prior to the end of the second treatment week. At the end of the trial, there were no significant differences between the two groups with respect to all outcome measures. There were no liver or kidney function abnormalities reported.","divisions":[{"label":"Title","span":{"begin":0,"end":7}}],"tracks":[]}